<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38216825</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study.</ArticleTitle><Pagination><StartPage>1075</StartPage><EndPage>1102</EndPage><MedlinePgn>1075-1102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-023-02754-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION/METHODS" NlmCategory="METHODS">EPOCH-US is an ongoing, retrospective, observational cohort study among individuals identified in the Healthcare Integrated Research Database (HIRD<sup>&#xae;</sup>) with &#x2265;&#x2009;12&#xa0;months of continuous health plan enrollment. Data were collected for the HIRD population (containing immunocompetent and immunocompromised [IC] individuals), individual IC cohorts (non-mutually exclusive cohorts based on immunocompromising condition and/or immunosuppressive [IS] treatment), and the composite IC population (all unique IC individuals). This study updates previous results with addition of the general population cohort and data specifically for the year of 2022 (i.e., Omicron wave period). To provide healthcare decision-makers the most recent trends, this study reports incidence rates (IR) and severity of first SARS-CoV-2 infection; and relative risk, healthcare utilization, and costs related to first COVID-19&#xa0;hospitalizations in the full year of 2022 and overall between April 2020 and December&#xa0;2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">These updated results showed a 2.9% prevalence of immune compromise in the population. From April 2020 through December 2022, the overall IR of COVID-19 was 115.7 per 1000 patient-years in the composite IC cohort and 77.8 per 1000 patient-years in the HIRD cohort. The composite IC cohort had a 15.4% hospitalization rate with an average cost of $42,719 for first COVID-19&#xa0;hospitalization. Comparatively, the HIRD cohort had a 3.7% hospitalization rate with an average cost of $28,848 for first COVID-19&#xa0;hospitalization. Compared to the general population, IC&#xa0;individuals had 4.3 to 23 times greater risk of hospitalization with first diagnosis of COVID-19. Between January and December 2022, hospitalizations associated with first COVID-19 diagnosis cost over $1&#xa0;billion, with IC&#xa0;individuals (~&#x2009;3% of the population) generating $310&#xa0;million (31%) of these costs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While only 2.9% of the population, IC individuals had a higher risk of COVID-19&#xa0;hospitalization and incurred higher healthcare costs across variants. They also disproportionately accounted for over 30% of total costs for first COVID-19&#xa0;hospitalization in 2022, amounting to ~&#x2009;$310&#xa0;million. These data highlight the need for additional preventive measures to decrease the risk of developing severe COVID-19 outcomes in vulnerable IC populations.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ketkar</LastName><ForeName>Amita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9287-0868</Identifier><AffiliationInfo><Affiliation>Carelon Research, Wilmington, DE, USA. amitagirish.ketkar@carelon.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willey</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Carelon Research, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glasser</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>AstraZeneca, Biopharmaceuticals Medical, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobie</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Xcenda, a Cencora company, Conshohocken, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenziger</LastName><ForeName>Cachet</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Carelon Research, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Carelon Research, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dube</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AstraZeneca, Biopharmaceuticals Medical, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirpara</LastName><ForeName>Sunny</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AstraZeneca, Biopharmaceuticals Medical, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Henry Ford Health, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verduzco-Gutierrez</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UT Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="Y">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Healthcare resource utilization</Keyword><Keyword MajorTopicYN="N">Immune suppression</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Primary immunodeficiency</Keyword><Keyword MajorTopicYN="N">Transplant</Keyword></KeywordList><CoiStatement>Christine Dube, Lisa Glasser, and Sunny Hirpara are employees and shareholders of AstraZeneca. Monica Verduzco-Gutierrez has received honoraria and travel to give lectures related to long COVID-19; unrelated to this work, she has been a consultant with AbbVie (consultant/advisor, speakers bureau), Merz (consultant/advisor, speakers bureau), Ipsen (grant/research, consultant/advisor, speakers bureau), Medtronic (consultant/advisor), and Piramal (speakers bureau). Dennis Cunningham has been a consultant/advisor for AstraZeneca. Dennis Cunnigham had an affiliation with Henry Ford Health, Detroit, MI, USA at the time of study which has changed since to Michigan State University, MI, USA. Carelon Research received funding from AstraZeneca to conduct this study. Amita Ketkar, Vincent Willey, Cachet Wenziger, and Chia-Chen Teng are employees of Carelon Research (formerly known as HealthCore). Amita Ketkar and Vincent Willey are shareholders of Elevance Health (formerly Anthem), which is the parent company of Carelon Research (formerly HealthCore). Casey Dobie is an employee of Xcenda, a Cencora company, and a consultant for AstraZeneca.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38216825</ArticleId><ArticleId IdType="pmc">PMC10879378</ArticleId><ArticleId IdType="doi">10.1007/s12325-023-02754-0</ArticleId><ArticleId IdType="pii">10.1007/s12325-023-02754-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 145 published 1 June 2023: World Health Organization; 2023 [updated June 1, 2023]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2023. Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID Data Tracker. Weekly Update for the United States Atlanta, GA: Department of Health and Human Services, CDC; 2023 [updated June 22, 2023]. https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 30 June 2023.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID Data Tracker. Daily Update for the United States Atlanta, GA: U.S. Department of Health &amp; Human Services, CDC; 2023 [updated February 23, 2023]. https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 28 Feb 2023.</Citation></Reference><Reference><Citation>Walmsley T, Rose A, John R, et al. Macroeconomic consequences of the COVID-19 pandemic. Econ Model. 2023;120:106147. doi: 10.1016/j.econmod.2022.106147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.econmod.2022.106147</ArticleId><ArticleId IdType="pmc">PMC9768433</ArticleId><ArticleId IdType="pubmed">36570545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hl&#xe1;vka J, Rose A. Covid-19&#x2019;s total cost to the U.S. economy will reach $14 trillion by end of 2023 [Internet]. (2023). Available from: https://healthpolicy.usc.edu/article/covid-19s-total-cost-to-the-economy-in-uswill-reach-14-trillion-by-end-of-2023-new-research/.</Citation></Reference><Reference><Citation>Zabidi NZ, Liew HL, Farouk IA, et al. Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies. Viruses. 2023;15(4):944. doi: 10.3390/v15040944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040944</ArticleId><ArticleId IdType="pmc">PMC10145020</ArticleId><ArticleId IdType="pubmed">37112923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Lou J, Chan SY, et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nat Med. 2022;28(8):1715&#x2013;1722. doi: 10.1038/s41591-022-01877-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01877-1</ArticleId><ArticleId IdType="pmc">PMC9388371</ArticleId><ArticleId IdType="pubmed">35710987</ArticleId></ArticleIdList></Reference><Reference><Citation>Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 lineage&#x2014;United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95&#x2013;99. doi: 10.15585/mmwr.mm7003e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7003e2</ArticleId><ArticleId IdType="pmc">PMC7821772</ArticleId><ArticleId IdType="pubmed">33476315</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong D. Alpha, Beta, Delta, Gamma: what&#x2019;s important to know about SARS-CoV-2 variants of concern? Can Med Assoc J. 2021;193(27):E1059. doi: 10.1503/cmaj.1095949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.1095949</ArticleId><ArticleId IdType="pmc">PMC8342008</ArticleId><ArticleId IdType="pubmed">34253551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad F, Cisewski J, Xu J, Anderson R. Provisional mortality data-United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72:488&#x2013;492. doi: 10.15585/mmwr.mm7218a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7218a3</ArticleId><ArticleId IdType="pmc">PMC10168603</ArticleId><ArticleId IdType="pubmed">37141156</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. End of the Federal COVID-19 Public Health Emergency(PHE) Declaration Atlanta, GA: Centers for Disease Control and Prevention; 2023 [updated May&#xa0;5, 2023]. https://www.cdc.gov/coronavirus/2019-ncov/your-health/end-of-phe.html. Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus Disease (COVID-19) Pandemic: Overview: World Health Organization; 2023 [updated June 21, 2023]. https://www.who.int/europe/emergencies/situations/covid-19. Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>Coaston J. The new phase of the pandemic is Covid exhaustion: we&#x2019;re over covid. Are we able to move on from it for good? New York Times. 2022 March 9, 2022.</Citation></Reference><Reference><Citation>Wadman M. When is a pandemic &#x2018;over&#x2019;? Science. 2022;375(6585):1077&#x2013;1078. doi: 10.1126/science.adb1919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adb1919</ArticleId><ArticleId IdType="pubmed">35271317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland Clinic. No, the COVID-19 pandemic isn&#x2019;t over: ending the U.S. public health emergency delcaration doesn&#x2019;t mean COVID-19 is gone. Cleveland, OH: Cleveland Clinic; 2023. https://health.clevelandclinic.org/is-the-pandemic-over/. Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>Rathke B, Yu H, Huang H. What remains now that the fear has passed? Developmental trajectory analysis of COVID-19 pandemic for co-occurrences of Twitter, Google Trends, and public health data. Disaster Med Public Health Prep. 2023;17:e471.</Citation><ArticleIdList><ArticleId IdType="pubmed">37317615</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 148 published 22 June 2023: World Health Organization; 2023 [updated June 22, 2023]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2023. Accessed 11 Sept 2023.</Citation></Reference><Reference><Citation>Abbasi J. Researchers tie severe immunosuppression to chronic COVID-19 and virus variants. JAMA. 2021;325(20):2033&#x2013;2035. doi: 10.1001/jama.2021.7212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7212</ArticleId><ArticleId IdType="pubmed">33950236</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff K, Smith C, Silveira L, et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J. 2021;40(4):e137&#x2013;e145. doi: 10.1097/INF.0000000000003043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003043</ArticleId><ArticleId IdType="pubmed">33538539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan C, Minc A, Caceres J, et al. Predicting severe outcomes in Covid-19 related illness using only patient demographics, comorbidities and symptoms. Am J Emerg Med. 2021;45:378&#x2013;384. doi: 10.1016/j.ajem.2020.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.09.017</ArticleId><ArticleId IdType="pmc">PMC7480533</ArticleId><ArticleId IdType="pubmed">33046294</ArticleId></ArticleIdList></Reference><Reference><Citation>SeyedAlinaghi S, Abbasian L, Solduzian M, et al. Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. Eur J Med Res. 2021;26(1):41. doi: 10.1186/s40001-021-00513-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00513-x</ArticleId><ArticleId IdType="pmc">PMC8100933</ArticleId><ArticleId IdType="pubmed">33957992</ArticleId></ArticleIdList></Reference><Reference><Citation>Velayos FS, Dusendang JR, Schmittdiel JA. Prior immunosuppressive therapy and severe illness among patients diagnosed with SARS-CoV-2: a community-based study. J Gen Intern Med. 2021;36(12):3794&#x2013;3801. doi: 10.1007/s11606-021-07152-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-07152-2</ArticleId><ArticleId IdType="pmc">PMC8477718</ArticleId><ArticleId IdType="pubmed">34581984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofsink Q, Haggenburg S, Lissenberg-Witte BI, et al. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study. EClinicalMedicine. 2023;61:102040. doi: 10.1016/j.eclinm.2023.102040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102040</ArticleId><ArticleId IdType="pmc">PMC10270678</ArticleId><ArticleId IdType="pubmed">37337616</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulia DL, Wallace M, Roper LE, et al. Interim recommendations for use of bivalent mRNA COVID-19 vaccines for persons aged &#x2265; 6&#xa0;months&#x2014;United States, April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(24):657&#x2013;662. doi: 10.15585/mmwr.mm7224a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7224a3</ArticleId><ArticleId IdType="pmc">PMC10328466</ArticleId><ArticleId IdType="pubmed">37319020</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, Dube S, Lu Y, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023;35:100747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10730312</ArticleId><ArticleId IdType="pubmed">38115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19&#xa0;hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Am. 2023;20:100461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9987330</ArticleId><ArticleId IdType="pubmed">36890850</ArticleId></ArticleIdList></Reference><Reference><Citation>Malahe SRK, Hoek RAS, Dalm VASH, et al. Clinical characteristics and outcomes of immunocompromised patients with coronavirus disease 2019 caused by the omicron variant: a prospective observational study. Clin Infect Dis. 2022;76(3):e172&#x2013;e178. doi: 10.1093/cid/ciac571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac571</ArticleId><ArticleId IdType="pmc">PMC9384537</ArticleId><ArticleId IdType="pubmed">35869843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketkar A, Willey V, Pollack M, et al. Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study. Curr Med Res Opin. 2023;39(8):1103&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">37431293</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Census Bureau. Community Survey 5-Year Data Profile (2015&#x2013;2019) Washington, DC: U.S. Census Bureau; 2019. https://www.census.gov/programs-surveys/acs/data.html. Accessed 11 Sept 2023.</Citation></Reference><Reference><Citation>Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676&#x2013;682. doi: 10.1093/aje/kwq433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq433</ArticleId><ArticleId IdType="pubmed">21330339</ArticleId></ArticleIdList></Reference><Reference><Citation>Eicheldinger C, Bonito A. More accurate racial and ethnic codes for Medicare administrative data. Health Care Financ Rev. 2008;29(3):27&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195038</ArticleId><ArticleId IdType="pubmed">18567241</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Bureau of Labor Statistics. CPI Inflation Calculator Washington, DC: U.S. Bureau of Labor Statistics; 2023. https://www.bls.gov/data/inflation_calculator.htm. Accessed 11 Sept 2023.</Citation></Reference><Reference><Citation>Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547&#x2013;2548. doi: 10.1001/jama.2016.16477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.16477</ArticleId><ArticleId IdType="pubmed">27792809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace BI, Kenney B, Malani PN, Clauw DJ, Nallamothu BK, Waljee AK. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018&#x2013;2019. JAMA Netw Open. 2021;4(5):e214920-e. doi: 10.1001/jamanetworkopen.2021.4920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.4920</ArticleId><ArticleId IdType="pmc">PMC8138687</ArticleId><ArticleId IdType="pubmed">34014329</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8(7):ofab353. doi: 10.1093/ofid/ofab353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab353</ArticleId><ArticleId IdType="pmc">PMC8320282</ArticleId><ArticleId IdType="pubmed">34337100</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung MW, Dayam RM, Shapiro JR, et al. Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in adult patients with immune-mediated inflammatory diseases. J Immunol. 2023;211(3):351&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10352588</ArticleId><ArticleId IdType="pubmed">37326480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661&#x2013;662. doi: 10.1056/NEJMc2108861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2108861</ArticleId><ArticleId IdType="pmc">PMC8262620</ArticleId><ArticleId IdType="pubmed">34161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant. 2021;36(9):1709&#x2013;1716. doi: 10.1093/ndt/gfab179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab179</ArticleId><ArticleId IdType="pmc">PMC8194560</ArticleId><ArticleId IdType="pubmed">33999200</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. Lancet Reg Health Am. 2022;9:100198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841530</ArticleId><ArticleId IdType="pubmed">35187521</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of severe acute respiratory syndrome coronavirus&#xa0;2 messenger RNA vaccines for preventing coronavirus disease 2019&#xa0;hospitalizations in the United States. Clin Infect Dis. 2022;74(9):1515&#x2013;1524. doi: 10.1093/cid/ciab687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab687</ArticleId><ArticleId IdType="pmc">PMC8436392</ArticleId><ArticleId IdType="pubmed">34358310</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657&#x2013;663. doi: 10.1038/s41586-021-04385-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan K, Karim F, Ganga Y, et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat Commun. 2022;13(1):4686. doi: 10.1038/s41467-022-32396-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32396-9</ArticleId><ArticleId IdType="pmc">PMC9364294</ArticleId><ArticleId IdType="pubmed">35948557</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock TP, Brown JC, Zhou J, et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein. Preprint. BioRxiv. 2022:2021.12.31.474653.</Citation></Reference><Reference><Citation>Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422&#x2013;3313. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7(8):1161&#x2013;1179. doi: 10.1038/s41564-022-01143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett BJ, Kurshan A, Thakur N, et al. Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5. Preprint. BioRxiv. 2022:2022.05.25.493397.</Citation></Reference><Reference><Citation>De Vito A, Colpani A, Saderi L, et al. Impact of early SARS-CoV-2 antiviral therapy on disease progression. Viruses. 2022;15(1):71. doi: 10.3390/v15010071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010071</ArticleId><ArticleId IdType="pmc">PMC9865563</ArticleId><ArticleId IdType="pubmed">36680111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmah L, Abarikwu SO, Arero AG, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74(6):1255&#x2013;1278. doi: 10.1007/s43440-022-00388-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00388-7</ArticleId><ArticleId IdType="pmc">PMC9309032</ArticleId><ArticleId IdType="pubmed">35871712</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603(7902):700&#x2013;705. doi: 10.1038/s41586-022-04462-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose Navarrete GB. SARS-CoV-2 infection and death rates among maintenance dialysis patients during delta and early omicron waves&#x2014;United States, June 30, 2021&#x2013;September 27, 2022. MMWR Morb Mortal Wkly Rep. 2023;2023(72):871&#x2013;876. doi: 10.15585/mmwr.mm7232a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a4</ArticleId><ArticleId IdType="pmc">PMC10415006</ArticleId><ArticleId IdType="pubmed">37561674</ArticleId></ArticleIdList></Reference><Reference><Citation>Amruta N, Chastain WH, Paz M, et al. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev. 2021;58:1&#x2013;15. doi: 10.1016/j.cytogfr.2021.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.02.002</ArticleId><ArticleId IdType="pmc">PMC7894219</ArticleId><ArticleId IdType="pubmed">33674185</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakibuzzaman M, Hassan A, Hayee S, et al. Exacerbation of pre-existing neurological symptoms with COVID-19 in patients with chronic neurological diseases: an updated systematic review. Cureus. 2022;14(9):e29297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578565</ArticleId><ArticleId IdType="pubmed">36277564</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>